RESUMEN
A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Ifosfamida/uso terapéutico , Interferón-alfa/uso terapéutico , Neoplasias Pulmonares/tratamiento farmacológico , Adulto , Anciano , Evaluación de Medicamentos , Femenino , Humanos , Ifosfamida/efectos adversos , Interferón alfa-2 , Masculino , Persona de Mediana Edad , Proteínas RecombinantesRESUMEN
Lung tumours of non small cell pathology were cultured by clonogenic assay in several media. Culture was successful in spleen conditioned medium, but only 57% grew and low plating efficiencies (PE) meant that only 23% of the original number produced significant drug results. Comparison of rat erythrocyte lysate (REL) medium with serum free defined medium (HITES) and HITES + 10% FBS demonstrated clear enhancement of PE in REL although growth was 100% successful in all these media. Ninety-three percent of samples tested against drugs in REL produced significant results. A later comparison of REL with McCoy's 5A + rbc +/- hydrocortisone produced relatively poor culture success for these 3 media and equivocal growth patterns. Low PE was attributed to age of rats used for rbc. Vindesine and cis-platinum cytotoxicity in spleen conditioned medium were 61% and 15% sensitivity respectively. These do not concur with clinical experience but the figures for overt resistance, at 39% and 69%, correspond with expected non-responders to these regimes. Drug testing in REL produced figures correlating more closely with clinical performance at 45% sensitivity to platinum and 36% of patients sensitive to both drugs, but the vindesine sensitivity at 55% is again discrepant with performance of this drug as a single agent.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/patología , Ensayo de Unidades Formadoras de Colonias , Medios de Cultivo , Neoplasias Pulmonares/patología , Ensayo de Tumor de Célula Madre , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Cisplatino/farmacología , Cisplatino/uso terapéutico , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Vindesina/farmacología , Vindesina/uso terapéuticoRESUMEN
Ovarian tumours were cultured by clonogenic assay and drug sensitivity profiles obtained for cis-platinum, adriamycin and phosphoramide mustard. Results were correlated with clinical outcome. Two hundred samples were received from 106 patients and 115/167 with malignant cytology (69%) were cultured successfully. Drug results were obtained on 71 samples and in untreated patients 60% of samples (48% of patients) were markedly sensitive to cis-platinum and 87% of samples (76% of patients) were sensitive to adriamycin. Eighty-one percent of cases sensitive to adriamycin were also sensitive to cis-platinum. Two of 7 samples were sensitive to phosphoramide mustard; the remainder were resistant. Eighty percent of samples from treated patients were resistant in vitro to drugs already received. Seventy-one samples from 57 patients were suitable for drug study. Forty-eight patients received chemotherapy, but only 23 received the drugs tested. Clinical correlations showed that in vitro sensitivity to cis-platinum and adriamycin was related to a good clinical response. No correlations were observed between cis-platinum and adriamycin resistance in vitro and clinical outcome. Unexpected relationships, however, were observed between cis-platinum resistance and failure to respond to other alkylating agents received singly. No such relationship has been demonstrated for adriamycin.